Compare · SIBN vs WST
SIBN vs WST
Side-by-side comparison of SI-BONE Inc. (SIBN) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SIBN and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $24.52B, about 28.0x SIBN ($875.8M).
- SIBN has been more active in the news (14 items in the past 4 weeks vs 1 for WST).
- WST has more recent analyst coverage (18 ratings vs 12 for SIBN).
- Company
- SI-BONE Inc.
- West Pharmaceutical Services Inc.
- Price
- -
- -
- Market cap
- $875.8M
- $24.52B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 14
- 1
- Recent ratings
- 12
- 18
SI-BONE Inc.
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest SIBN
- SEC Form 144 filed by SI-BONE Inc.
- Chief Executive Officer Francis Laura sold $1,088,201 worth of shares (55,807 units at $19.50) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Op & Financial Officer Maheshwari Anshul sold $337,138 worth of shares (16,975 units at $19.86) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 234,920 units (SEC Form 4)
- SEC Form 144 filed by SI-BONE Inc.
- SEC Form 144 filed by SI-BONE Inc.
- Chief Executive Officer Francis Laura sold $279,065 worth of shares (14,956 units at $18.66), decreasing direct ownership by 2% to 493,900 units (SEC Form 4) (tax liability)
- SVP, Ops & Adm/Chief Legal Ofr Pisetsky Michael A. sold $69,411 worth of shares (3,725 units at $18.63), decreasing direct ownership by 1% to 273,650 units (SEC Form 4) (tax liability)
- Chief Financial Officer Maheshwari Anshul sold $87,016 worth of shares (4,665 units at $18.65), decreasing direct ownership by 2% to 251,895 units (SEC Form 4) to cover withholding tax
- SEC Form SCHEDULE 13G filed by SI-BONE Inc.
- Director Dunn Jeffrey W exercised 20,000 shares at a strike of $4.68 and sold $369,214 worth of shares (20,000 units at $18.46) as part of a pre-agreed trading plan (SEC Form 4)
Latest WST
- SVP & Chief Financial Officer Mcmahon Robert W. converted options into 7,149 shares and covered exercise/tax liability with 3,109 shares, increasing direct ownership by 136% to 7,021 units (SEC Form 4)
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Declares Quarterly Dividend
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target